Blogs | MedChemExpress

PKI-166 is a Selective and Orally Bioavailable EGFR Autophosphorylation Inhibitor

PKI-166 is an orally active EGFR tyrosine kinase inhibitor and inhibits pancreatic cancers. Combined with Gemcitabine produces a decrease in tumor growth.
BCI-215 is a Tumor Cell-Selective DUSP-MKP Inhibitor

BCI-215 is a potent and tumor cell-selective DUSP-MKP inhibitor without affecting normal cells. Anti-migratory and proapoptotic activities in cancer cells.
PF-573228 is a Potent and Selective FAK Inhibitor

PF-573228 is a potent and selective FAK inhibitor and serves as a useful tool to dissect the functions of FAK in normal and cancer cells.
A-366 is a Potent Histone Methyltransferase G9a Inhibitor

A-366 is a potent G9a-inhibitor without affect other histone methyltransferases. A-366 significantly results in tumor growth inhibition in leukemia.
AZD4547 is a Potent FGFR Family Inhibitor

AZD4547 potently inhibits the FGFR family with low IC50s. AZD4547 inhibits FGF/FGFR downstream signaling through FRS2, PLCγ, and MAPK at the cellular level.
CGP52411 is an Orally Active and ATP-Competitive EGFR Inhibitor

CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with good anticancer activity.
PI-103 is a Potent PI3K and mTOR Inhibitor

PI-103 is a potent PI3K and mTOR inhibitor, it also inhibits DNA-PK. PI-103 exhibits antiproliferative properties in a panel of human cancer cell lines.
COTI-2 is an Orally Available Mutant p53 Activator

COTI-2 is an orally available third generation activator of p53 mutant forms by inhibiting the PI3K/AKT/mTOR pathway. COTI-2 has has anti-cancer activity.
CC-223 is an Orally Bioavailable mTOR Kinase Inhibitor

CC-223 is an orally bioavailable mTOR kinase inhibitor and demonstrates mTORC1/2 and growth inhibitory activity across a variety of tumor cell types.
GPP78 is a Nampt Inhibitor and an Autophagy Inducer

GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (16)